TABLE 4.
Prognostic factors for the overall survival in the 326 patients classified by the kind of adjuvant agents (GEM or S‐1)
| Variables | Univariate | Multivariate | ||
|---|---|---|---|---|
| Hazard ratio (95% confidence interval) | p | Hazard ratio (95% confidence interval) | p | |
| GEM (n = 166) | ||||
| Sex (Male/Female) | 1.24 (0.88–1.75) | 0.219 | ||
| Age (≥65 years/<65 years) | 1.12 (0.78–1.60) | 0.540 | ||
| ECOG performance status (1/0) | 1.46 (1.02–2.09) | 0.037 | 1.29 (0.89–1.87) | 0.177 |
| Residual tumor status (R1/R0) | 1.99 (1.24–3.20) | 0.004 | 1.48 (0.91–2.41) | 0.117 |
| Primary tumor status (T3‐T4/T1‐2) | 4.22 (1.97–9.07) | <0.001 | 3.40 (1.56–7.42) | 0.002 |
| Regional lymph node status (N1/N0) | 1.89 (1.30–2.75) | 0.001 | 1.35 (0.90–2.01) | 0.143 |
| CA19‐9 (>37 U/ml/≤37 U/ml) | 1.84 (1.24–2.73) | 0.003 | 1.54 (1.02–2.32) | 0.040 |
| hENT1 expressions | ||||
| IHC with SP120 (Strong/Moderate+Weak+Absent) | 0.78 (0.42–1.45) | 0.430 | ||
| IHC with SP120 (Strong+Moderate/Weak+Absent) | 0.95 (0.65–1.38) | 0.786 | ||
| IHC with SP120 (Strong+Moderate+Weak/Absent) | 1.01 (0.68–1.50) | 0.952 | ||
| S‐1 (n = 160) | ||||
| Sex (Male/Female) | 1.07 (0.72–1.61) | 0.728 | ||
| Age (≥65 years/<65 years) | 1.19 (0.79–1.79) | 0.404 | ||
| ECOG performance status (1/0) | 1.08 (0.70–1.67) | 0.716 | ||
| Residual tumor status (R1/R0) | 1.89 (1.10–3.23) | 0.020 | 1.90 (1.11–3.27) | 0.020 |
| Primary tumor status (T3‐T4/T1‐2) | 1.50 (0.73–3.10) | 0.269 | ||
| Regional lymph node status (N1/N0) | 2.02 (1.26–3.25) | 0.004 | 1.83 (1.13–2.97) | 0.014 |
| CA19‐9 (>37 U/ml/≤37 U/ml) | 2.11 (1.35–3.29) | 0.001 | 2.02 (1.29–3.17) | 0.002 |
| hENT1 expressions | ||||
| IHC with SP120 (Strong/Moderate+Weak+Absent) | 1.51 (0.81–2.83) | 0.200 | ||
| IHC with SP120 (Strong+Moderate/Weak+Absent) | 1.75 (1.16–2.64) | 0.008 | 1.61 (1.06–2.45) | 0.027 |
| IHC with SP120 (Strong+Moderate+Weak/Absent) | 1.65 (0.98–2.78) | 0.061 | ||
Abbreviations: ECOG, Eastern Cooperative Oncology Group; GEM, gemcitabine; hENT1, human equilibrative nucleoside transporter‐1; IHC, immunohistochemistry.